306 related articles for article (PubMed ID: 29508003)
1. [Pharmacological treatment of rheumatoid arthritis and its comorbidities].
Krüger K
Internist (Berl); 2018 Apr; 59(4):341-351. PubMed ID: 29508003
[TBL] [Abstract][Full Text] [Related]
2. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
[TBL] [Abstract][Full Text] [Related]
3. Current concepts in the management of rheumatoid arthritis.
Tanaka Y
Korean J Intern Med; 2016 Mar; 31(2):210-8. PubMed ID: 26932398
[TBL] [Abstract][Full Text] [Related]
4. Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study.
Glinatsi D; Heiberg MS; Rudin A; Nordström D; Haavardsholm EA; Gudbjornsson B; Østergaard M; Uhlig T; Grondal G; Hørslev-Petersen K; van Vollenhoven R; Hetland ML
Trials; 2017 Apr; 18(1):161. PubMed ID: 28376912
[TBL] [Abstract][Full Text] [Related]
5. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
Ciubotariu E; Gabay C; Finckh A;
J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
[TBL] [Abstract][Full Text] [Related]
6. Treatment discontinuation in patients with very early rheumatoid arthritis in sustained simplified disease activity index remission after synthetic disease-modifying anti-rheumatic drug administration.
Kita J; Tamai M; Arima K; Nakashima Y; Suzuki T; Kawashiri SY; Iwamoto N; Okada A; Koga T; Yamasaki S; Nakamura H; Origuchi T; Ida H; Aoyagi K; Uetani M; Eguchi K; Kawakami A
Mod Rheumatol; 2012 Jun; 22(3):346-52. PubMed ID: 21960457
[TBL] [Abstract][Full Text] [Related]
7. The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis.
Cutolo M; Spies CM; Buttgereit F; Paolino S; Pizzorni C
Arthritis Res Ther; 2014 Nov; 16 Suppl 2(Suppl 2):S1. PubMed ID: 25608624
[TBL] [Abstract][Full Text] [Related]
8. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
Iannone F; Salaffi F; Fornaro M; Di Carlo M; Gentileschi S; Cantarini L; Lopalco G
Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
[TBL] [Abstract][Full Text] [Related]
9. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
[TBL] [Abstract][Full Text] [Related]
10. The use of conventional disease-modifying anti-rheumatic drugs in established RA.
Jurgens MS; Jacobs JW; Bijlsma JW
Best Pract Res Clin Rheumatol; 2011 Aug; 25(4):523-33. PubMed ID: 22137922
[TBL] [Abstract][Full Text] [Related]
11. What is the best treatment strategy for early RA?
Leirisalo-Repo M
Best Pract Res Clin Rheumatol; 2013 Aug; 27(4):523-36. PubMed ID: 24315052
[TBL] [Abstract][Full Text] [Related]
12. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
Combe B; Rincheval N; Benessiano J; Berenbaum F; Cantagrel A; Daurès JP; Dougados M; Fardellone P; Fautrel B; Flipo RM; Goupille P; Guillemin F; Le Loët X; Logeart I; Mariette X; Meyer O; Ravaud P; Saraux A; Schaeverbeke T; Sibilia J
J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185
[TBL] [Abstract][Full Text] [Related]
13. [Drug therapy of rheumatoid arthritis].
Arndt U; Rittmeister M; Möller B
Orthopade; 2003 Dec; 32(12):1095-103. PubMed ID: 14655006
[TBL] [Abstract][Full Text] [Related]
14. Advances in the management of rheumatoid arthritis.
Dale J
Scott Med J; 2015 Aug; 60(3):108-14. PubMed ID: 26122283
[TBL] [Abstract][Full Text] [Related]
15. [German guidelines for the treatment of rheumatoid arthritis with disease modifying anti-rheumatic drugs - What is new?].
Fiehn C
Dtsch Med Wochenschr; 2020 Apr; 145(7):474-479. PubMed ID: 32236929
[TBL] [Abstract][Full Text] [Related]
16. Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
Rannio T; Asikainen J; Hannonen P; Yli-Kerttula T; Ekman P; Pirilä L; Kuusalo L; Mali M; Puurtinen-Vilkki M; Kortelainen S; Paltta J; Taimen K; Kauppi M; Laiho K; Nyrhinen S; Mäkinen H; Isomäki P; Uotila T; Aaltonen K; Kautiainen H; Sokka T
Scand J Rheumatol; 2017 Nov; 46(6):425-431. PubMed ID: 28367663
[TBL] [Abstract][Full Text] [Related]
17. Are glucocorticoids harmful to bone in early rheumatoid arthritis?
Lems WF
Ann N Y Acad Sci; 2014 May; 1318():50-4. PubMed ID: 24739059
[TBL] [Abstract][Full Text] [Related]
18. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons.
Graudal N; Jürgens G
Arthritis Rheum; 2010 Oct; 62(10):2852-63. PubMed ID: 20560138
[TBL] [Abstract][Full Text] [Related]
19. Rheumatoid arthritis management of early disease.
Nam JL
Curr Opin Rheumatol; 2016 May; 28(3):267-74. PubMed ID: 26978129
[TBL] [Abstract][Full Text] [Related]
20. Early rheumatoid arthritis: strategies for prevention and management.
Combe B
Best Pract Res Clin Rheumatol; 2007 Feb; 21(1):27-42. PubMed ID: 17350542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
